Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparations of artemisinin or its derivatives and amodiaquine or its derivatives and preparation method thereof

A technology of amodiaquine and its derivatives, which is applied in the field of preparation and preparation of artemisinin or its derivatives and amodiaquine or its derivatives, which can solve the problems of medication errors, prone to fatigue, high toxicity, etc. , to achieve a good curative effect

Inactive Publication Date: 2005-12-21
桂林制药有限责任公司 +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage is that amodiaquine is more toxic than other antimalarial drugs. When the daily dose exceeds 52.8mg, it is prone to fatigue, dizziness, nausea, vomiting, abdominal pain, cyanosis, drug fever, etc., and a small number of red blood cells lack glucose 6-phosphate Patients with dehydrogenase can develop acute hemolytic anemia after medication, so WHO once prevented it from being used as a drug for treating malaria
[0005] At present, the WHO recommends the combination of amodiaquine and artemisinin drugs. However, since artemisinin or its derivatives and amodiaquine or its derivatives are prepared into tablets separately, it is very easy to take drugs. Mistakes, especially not suitable for the elderly and children, need to be improved urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Embodiment 1 prepares the tablet in compound preparation

[0042] Composition

weight

effect

I

II

III

artesunate

starch

lactose

Dextrin

Sodium dodecyl sulfate

Sodium carboxymethyl starch

Amodiaquine

starch

lactose

Dextrin

Sodium carboxymethyl starch

Sodium carboxymethyl starch

Hydroxypropyl Cellulose

microcrystalline cellulose

Magnesium stearate

50 grams

20 grams

12 grams

4 grams

4 grams

10gram

150 grams

50 grams

30 grams

10gram

10gram

10gram

10gram

20 grams

10gram

active ingredient

filler

filler

filler

Solubilizers

disintegrant

active ingredient

filler

filler

filler

disintegrant

disintegrant

disintegrant

disintegrant

lubricant

total weight

400 grams

...

Embodiment 2

[0049] Embodiment 2 prepares the tablet in compound preparation

[0050] Composition

weight

effect

I

artesunate

starch

lactose

Dextrin

Sodium dodecyl sulfate

Sodium carboxymethyl starch

100 g

25 grams

16 grams

8 grams

6 grams

15 grams

active ingredient

filler

filler

filler

Solubilizers

disintegrant

II

III

Amodiaquine

starch

lactose

Dextrin

Sodium carboxymethyl starch

Sodium carboxymethyl starch

Hydroxypropyl Cellulose

microcrystalline cellulose

Magnesium stearate

300 grams

60 grams

35 grams

10gram

15 grams

13 grams

13 grams

22 grams

12 grams

active ingredient

filler

filler

filler

disintegrant

disintegrant

disintegrant

disintegra...

Embodiment 3

[0057] Embodiment 3 prepares the tablet in compound preparation

[0058] Composition

weight

effect

artesunate

Amodiaquine

starch

lactose

Dextrin

Sodium dodecyl sulfate

Sodium carboxymethyl starch

Hydroxypropyl Cellulose

microcrystalline cellulose

Magnesium stearate

50 grams

150 grams

70 grams

43 grams

13 grams

4 grams

30 grams

10gram

20 grams

10gram

active ingredient

active ingredient

filler

filler

filler

Solubilizers

disintegrant

disintegrant

disintegrant

lubricant

total weight

400 grams

[0059] 2. Preparation method

[0060] (1) After pulverizing the raw and auxiliary materials of the above-mentioned prescription amount, pass through a 60 mesh sieve, mix uniformly, cross a 40 mesh sieve, add magnesium stearate, and mix uniformly;

[0061] (2) According to the conv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a preparation made up by using artemisinin or its derivative and amodiaquine or its derivative and its preparation method. Said preparation is formed from active component and pharmaceutically-acceptable solid additive, the described active component is the mixture formed from artemisinin or its derivative and amodiaquine or its derivative. Said preparation can high-effectively and durably kill plasmodia.

Description

technical field [0001] The invention relates to a compound preparation of artemisinin or its derivatives and amodiaquine for preventing and treating malaria and a preparation method thereof. Background technique [0002] Malaria is one of the most common diseases in the tropics and subtropics. At present, malaria is prevalent in nearly 100 countries around the world, and more than 2.5 billion people live in areas with high incidence of malaria. The number of malaria patients is 300 to 500 million people every year, and 2 to 3 million people are newly infected every year. 1 to 3 million people. What is more serious at present is that Plasmodium falciparum has developed resistance to commonly used antimalarial drugs through genetic mutation or adaptive ability, and has spread at a very high speed in various malaria regions around the world, especially in Southeast Asia. Although all countries are developing new antimalarial drugs for the prevention and treatment of drug-resi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/47
Inventor 严啸华郑清四龚秋燕
Owner 桂林制药有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products